Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters

Abstract

We aimed to determine the presence of SKI-interacting protein (SKIP) expression in malignant pleural mesothelioma (MPM) and its effect on prognosis by investigating SKIP correlation with the Ki-67 proliferation index and prognostic parameters. Pathological preparations of the patients diagnosed with MPM between 2006 and 2012 were evaluated. Immunohistochemical analyses were performed to evaluate the expression of SKIP and the Ki-67 proliferation index. Correlations between SKIP expression, clinicopathological factors and survival were investigated. Survival data were calculated using the Kaplan-Meier method, and Cox regression analysis was used to evaluate the prognostic value of the variables. In total, 52 patients were evaluated in the study; 36 of them were male and 16 were female. The mean age of the patients was 62.3 ±12.2 years. The median overall survival period was 8.5 months. Factors negatively affecting general survival in the univariate analysis included high SKIP expression, Ki-67 proliferative index over 30%, presence of non-epithelioid type MPM and stage III-IV disease (p < 0.05). Cox regression analysis revealed that high SKIP expression, high Ki-67 proliferative index and presence of non-epithelioid type MPM are independent factors that affect the survival rate. Higher SKIP expression is associated with poor prognosis in MPM.

SNW1 is a prognostic biomarker in prostate cancer

“…Data from RNA sequencing of prostate cancers do not show major SNW1 mRNA expression changes [21], suggesting that stabilization may account for the increased levels identified by immunohistochemistry. However, data supporting SNW1 up regulation in malignant tumors comes from breast cancer [10], hepatocellular carcinoma [11], bladder cancer [12] and malignant pleural mesothelioma [13].…”

“…Accordingly, associations of SNW1 up regulation with unfavorable tumor features have also been reported from several other malignancies. For example, SNW1 overexpression is linked to high tumor grade and accelerated cell proliferation in breast cancer [10], and to poor prognosis in urinary bladder cancer, hepatocellular carcinoma, and malignant pleural mesothelioma [11–13].…”

“…For example, overexpression of SNW1 was reported in 43% of breast cancers [10], 50% of liver cancers [11], 30% of bladder cancers [12] and 40% of malignant pleural mesothelioma [13]. High SNW1 expression was associated with high tumor grade and proliferation in breast cancer [10] and with poor prognosis in the other above-mentioned tumor types [11–13]. Given its functional association with the androgen receptor, it appears possible that SNW1 expression may also be relevant in prostate cancer biology.…”

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

“…Malignant pleural mesothelioma (MPM) is a highly aggressive tumour arising from the pleural cavities [1, 2]. Despite treatment, MPM patients have poor prognosis with a median survival of approximately 12 months [3–5]. The state-of-the-art systemic treatment of unresectable and advanced MPM is chemotherapy with a combination of cisplatin and pemetrexed [6, 7].…”